DANOCRINE

LOE Approaching

danazol

NDAORALCAPSULEPriority Review
Approved
Jun 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

CLINICAL PHARMACOLOGY Danazol suppresses the pituitary-ovarian axis. This suppression is probably a combination of depressed hypothalamic-pituitary response to lowered estrogen production, the alteration of sex steroid metabolism, and interaction of danazol with sex hormone receptors. The only…

Clinical Trials (1)

NCT04173494Phase 3Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Started Feb 2020
195 enrolled
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis